World Multiple Myeloma Drug Treatment Market 2012-2022

September 2012 | 136 pages | ID: W677B1E0129EN
Visiongain

Abstracts

Your guide to trends and revenue prospects for treating multiple myeloma

See what the future holds for products to treat multiple myeloma. Visiongain's updated report gives you revenue predictions to 2022. There you find data, trends, opportunities and commercial prospects.

Our study lets you assess forecasted sales at overall world market, product and national level. Those analyses help you see the future of that industry and market.

In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, news, research and development (R&D) and business outlooks. You receive 42 tables, 39 charts and a research interview.

We show where growth can occur. Our work lets you investigate the most lucrative areas, helping you stay ahead in knowledge.

The following sections highlight what you discover in the report.

Our work shows you prospects for the world market and leading products

In addition to analysis of the overall world market, our study shows you revenue forecasting of five products to 2022:

• Revlimid
• Thalomid
• Actimid
• Velcade
• Kyprolis.

Also, you see how five late-stage drug candidates - Elotuzumab, MLN9708, Perifosine, Faridak and Aplidin - can perform to 2022. See potential revenues. Our investigation shows you business research and analyses with individual sales forecasts and discussions.

Our work also breaks overall world revenue into leading countries.

National market prospects - which countries will have the highest growth?

There are many commercial opportunities in developed and developing countries, our study shows. You discover individual revenue forecasts to 2022 for eleven national markets:

• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC nations).

There will be high revenue growth in the established pharma markets, but also opportunities in developing countries, especially India and China. Also, product launches from 2012 onwards will benefit leading national markets. Our report shows opportunities for new drugs.

Research and development - you see trends and prospects for technologies

What about the R&D pipeline for that area of oncology? Our work shows you developmental trends by phase. You investigate developments including these:

• Monoclonal antibodies (mAbs) and other biologics
• Small-molecule products
• Protein kinase inhibition
• HDAC inhibition
• Inhibition of protein synthesis and induction of apoptosis.

Beyond proteasome inhibitors and immunomodulators, promising candidates include HDAC inhibitors, kinase inhibitors and orally-bioavailable second-generation proteasome inhibitors.

Discover how technology can change the treatment of multiple myeloma, finding progress and outlooks. Our investigation shows activities of companies treating that blood cancer.

Leading companies and revenue prospects

What will happen next? The pharmaceutical industry will improve treatments for multiple myeloma and increase revenues from 2012 to 2022. The R&D pipeline is strong.

Overall world revenue for that market area will reach $9.9bn in 2015, our report forecasts. Incidence and prevalence of multiple myeloma worldwide will stimulate demand to 2022.

Also, biological drugs will transform the market, improving treatment of blood cancer, including neoplasm in bone marrow.

In our study you find discussions and analyses of Celgene, Johnson & Johnson, Novartis, Onyx and other developers and manufacturers. This decade, many opportunities will arise for companies treating cancers.

Nine ways World Multiple Myeloma Drug Treatment Market 2012-2022 helps you

In particular, then, our report gives you the following knowledge on the topic:

• Forecasted revenue to 2022 for the overall world market - find the industry's prospects
• Potential revenues of 10 products to 2022 - analyse crucial developments
• Market forecasting to 2022 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - see leading national prospects
• Assessment of companies - find discussions of activities, products and outlooks
• Review of R&D pipelines - investigate developmental trends and progress
• Opinions on the sector - discover views, including a research interview
• Investigation of competition and opportunities influencing sales
• Discussions of what stimulates and restrains the industry and market
• Prospects for established companies and those seeking to launch products.

That work gives you quantitative and qualitative analyses with independent predictions. You receive information found only in our study.

There you find business intelligence to help you understand the future of the industry and market. You see where prospects are lucrative and growth is likely.

Discover how our work could benefit your research and analyses, saving you time too.

By ordering now you discover prospects for products to treat multiple myeloma

Visiongain's study is for everybody needing commercial analyses for the treatment of multiple myeloma. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government

Contents

1. EXECUTIVE SUMMARY

1.1 Multiple Myeloma Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods

2. OVERVIEW OF MULTIPLE MYELOMA

2.1 Multiple Myeloma Represents 10-15% of All Blood Cancers
2.2 Demographic Risk Variation in Multiple Myeloma
2.3 Medical Basis of Multiple Myeloma: Cancer of the Plasma Cells
2.4 Diagnosing Multiple Myeloma
2.5 Stages of the Disease
  2.5.1 MGUS
  2.5.2 Smouldering Multiple Myeloma
  2.5.3 The Durie-Salmon Staging System and the International Staging System
2.6 Treating Multiple Myeloma
  2.6.1 Induction Therapy
    2.6.1.1 SCT Following Induction Therapy
    2.6.1.2 Radiotherapy: Key Treatment for Plasmacytoma
    2.6.1.3 The Plateau: After Induction Therapy
  2.6.2 Consolidation Therapy
  2.6.3 Maintenance Therapy
  2.6.4 Salvage Therapy
  2.6.5 Present and Future Options for Treating Multiple Myeloma: Summary

3. THE GLOBAL MULTIPLE MYELOMA MARKET, 2012-2022

3.1 Overall Market Forecast, 2012-2022
3.2 Leading Product Classes, 2012
3.3 Leading Companies in the Market, 2012
  3.3.1 Celgene Corporation: Market Leaders
  3.3.2 Johnson & Johnson (Janssen): Proteosome Inhibitor and mAb Leader?
  3.3.3 Novartis: The Biggest Multiple Myeloma Pipeline
    3.3.3.1 Novartis' Multiple Myeloma Growth Strategy
  3.3.4 Bristol-Myers Squibb: Multiple Pipeline Candidates
  3.3.5 Onyx Pharmaceuticals: Lead Product Cafilzomib Approved
  3.3.6 Cephalon: Pioneering Oral Proteosome Inhibitors
  3.3.7 Aeterna Zentaris: High Potential
  3.3.8 Merck & Co. - Increasing Oncology Investment
  3.3.9 Takeda: Strong Pipeline
  3.3.10 Pfizer: Promising Pipeline
3.4 Leading National Markets
  3.4.1 The US will Continue to Dominate the Multiple Myeloma Market
  3.4.2 Japan: Revlimid Approval Driving Market Growth
  3.4.3 The Leading Five EU Countries
  3.4.4 BRIC Nations: Strong Projected Growth
    3.4.4.1 Brazil: Government Healthcare Investments Support Growth
    3.4.4.2 Russia: High Cancer Prevalence and Rapid Market Growth
    3.4.4.3 India: A Rapidly Developing Market
    3.4.4.4 China: Pursuing Domestic Oncology R&D

4. LEADING MULTIPLE MYELOMA TREATMENTS IN 2012

4.1 Immunomodulators and Proteasome Inhibitors Dominate the Market in 2012
4.2 Revlimid (Celgene Corporation)
  4.2.1 Drivers and Restraints for Revlimid, 2012
  4.2.2 Market Forecast for Revlimid, 2012-2022
4.3 Thalomid (Celgene Corporation)
  4.3.1Drivers and Restraints for Thalomid, 2012
  4.3.2 Market Forecast for Thalomid, 2012-2022
4.4 Actimid (Celgene Corporation)
  4.4.1Drivers and Restraints for Actimid, 2012
  4.4.2 Market Forecast for Actimid, 2012-2022
4.5 Velcade (Johnson & Johnson, Takeda)
  4.5.1 Drivers and Restraints for Velcade, 2012
  4.5.2 Market Forecast for Velcade, 2012-2022
4.6 Kyprolis (Onyx Pharmaceuticals)
  4.6.1 Drivers and Restraints for Kyprolis, 2012
  4.6.2 Market Forecast for Kyprolis, 2012-2022
4.7 Other Multiple Myeloma Therapy Options, 2012
  4.7.1 Doxil (Johnson & Johnson)
  4.7.2 Future Products

5. THE NEXT GENERATION OF MULTIPLE MYELOMA TREATMENTS

5.1 Overview of the Next Wave of Myeloma Products, 2012
5.2 Elotuzumab (Abbott/ Bristol-Myers Squibb)
  5.2.1 Elotuzumab: A New MAb Blockbuster?
  5.2.2 Revenue Forecast for Elotuzumab, 2012-2022
5.3 MLN9708 (Millennium)
  5.3.1 MLN9708: Changing the Treatment Paradigm?
  5.3.2 Revenue Forecast for MLN9708, 2012-2022
5.4 Perifosine (Aeterna Zentaris)
  5.4.1 Perifosine: The First of Many Protein Kinase Inhibitors?
  5.4.2 Revenue Forecast for Perifosine 2012-2022
5.5 Faridak (Novartis)
  5.5.1 Faridak: Leading a Wave of HDAC Inhibitors to Market?
  5.5.2 Revenue Forecast for Faridak, 2012-2022
5.6 Aplidin (PharmaMar)
  5.6.1 Aplidin: Inhibiting Protein Synthesis and Inducing Apoptosis
  5.6.2 Revenue Forecast for Aplidin, 2012-2022
5.7 Other Late-Stage Candidates

6. THE MULTIPLE MYELOMA R&D PIPELINE: SMALL-MOLECULE PRODUCTS, 2012

6.1 Phase III Compounds
6.2 Phase II Compounds
  6.2.1 Ridaforolimus (Ariad Pharmaceuticals, Merck)
  6.2.2 Dinaciclib (Merck, Ligand Pharmaceuticals)
  6.2.3 Enzastaurin (Eli Lilly)
  6.2.4 GSK2110183 (GlaxoSmithKline)
  6.2.5 Selumetinib (AstraZeneca)
  6.2.6 Ibrutinib (Pharmacyclics)
  6.2.7 Imetelstat (Geron)
  6.2.8 Istodax (Celgene)
  6.2.9 Givinostat (Italfarmaco)
  6.2.10 Kineret (Amgen)
  6.2.11 PD 0332991 (Pfizer)
  6.2.12 SCIO-469 (Johnson & Johnson)
  6.2.13 Dasatinib (Bristol-Myers Squibb)
  6.2.14 Treanda (Cephalon)
6.3 Phase I/II Compounds
  6.3.1 Torisel (Pfizer)
  6.3.2 Everolimus (Novartis)
  6.3.3 MLN8237 (Millennium Pharmaceuticals)
  6.3.4 Nexavar (Bayer, Onyx)
  6.3.5 ARRY-520 (Array BioPharma)
  6.3.6 AT7519 (Astex Therapeutics)
  6.3.7 Brostallicin (Pharmacia, NCI)
  6.3.8 AR-42 (Arno Therapeutics)
  6.3.9 KW-2478 (Kyowa)
  6.3.10 Noscapine (Janssen)
  6.3.11 TH-302 (Threshold Pharmaceuticals)
6.4 Phase I Compounds
  6.4.1 BMS-833923 (Bristol-Myers Squibb, Exelixis)
  6.4.2 Eltrombopag (GlaxoSmithKline)
  6.4.3 ENMD-2076 (EntreMed)
  6.4.4 Erivedge (NCI, Sidney Kimmel CCC, Genentech)
  6.4.5 Folotyn (Allos Therapeutics)
  6.4.6 Ganetespib (Synta Pharmaceuticals)
  6.4.7 GSK2110183 (GlaxoSmithKline)
  6.4.8 INK128 (Intllikine)
  6.4.9 IPI-504 (Infinity Pharmaceuticals)
  6.4.10 Marizomib (Nereus Pharmaceuticals)
  6.4.11 Vidaza (Celgene)
  6.4.12 Zarnestra (Johnson & Johnson)
6.5 Exploratory Preclinical Compounds

7. THE MULTIPLE MYELOMA R&D PIPELINE: BIOLOGICS, 2012

7.1 Phase III Biologic Compounds
7.2 Phase II Biologic Compounds
  7.2.1 T-Cells Targeted to MAGE- A3/6 and NY-ESO-1 (Adaptimmune)
  7.2.2 Siltuximab (Janssen)
  7.2.3 Avastin (Roche)
  7.2.4 Bexxar (GlaxoSmithKline)
  7.2.5 BHQ880 (Novartis)
  7.2.6 Donor Lymphocyte Infusion (MD Anderson Cancer Center)
  7.2.7 Erbitux (Eli Lilly)
  7.2.8 Expanded Natural Killer Cell Therapy (University of Arkansas, Celgene)
  7.2.9 GVAX (Cell Genesys)
  7.2.10 Hiltonol (Oncovir)
  7.2.11 KLH Vaccine (National Cancer Institute)
  7.2.12 Leukine (Genzyme)
  7.2.13 Mapatumumab (Human Genome Sciences)
  7.2.14 MDX-1097 (Immune System Therapeutics)
  7.2.15 Proleukin (Prometheus Labs)
  7.2.16 Rituxan (Biogen Idec, Roche)
  7.2.17 Stimuvax (Merck)
  7.2.18 VEGF Trap (Regeneron)
7.3 Phase I/II Compounds
  7.3.1 BT062 (Biotest Pharmaceuticals)
  7.3.2 HuMax-CD38 (GenMab)
  7.3.3 Milatuzumab (Immunomedics)
  7.3.4 MOR202 (MorphoSys)
  7.3.5 SNS01-T (Senesco Technologies)
7.4 Phase I Compounds
  7.4.1 ACE-041(Acceleron)
  7.4.2 DFRF4539A (Genentech)
  7.4.3 Lorvotuzumab Mertansine (ImmunuGen)
  7.4.4 LY2127399 (Eli Lilly)
  7.4.5 MFGR1877S (Genentech)
  7.5.6 Reolysin (Oncolytics)
  7.4.7 Dacetuzumab (Seattle Genetics)
7.5 Exploratory/Preclinical Compounds
7.6 Future Epigenetics-Based Treatments

8. QUALITATIVE ANALYSIS OF THE MULTIPLE MYELOMA MARKET

8.1 Strengths: Proven Commercial Potential of the Myeloma Market
8.2 Weaknesses: A Few Products Dominate the Market
8.3 Opportunities: Cancer Treatment is a Strong Business Segment in the Pharmaceutical Industry
8.4 Threats: Will Oncology Remain a Good Investment for Pharma?
8.5 Social: Adherence, Support and Education are Key Factors
8.6 Technological: The Rise of Cancer Biology
8.7 Economic: The Cost of Cancer Treatment
8.8 Political: Broadening and Narrowing Healthcare Provision in the 21st Century

9. RESEARCH INTERVIEW

9.1 Interview with an External Authority (Views Given Anonymously)
  9.1.1 Obesity is a Strong Risk Factor for Multiple Myeloma
  9.1.2 Multiple Myeloma Treatment: Proactive versus Reactive
  9.1.3 Treatment Options for Obese Patients
  9.1.4 Multiple Myeloma Incidence Will Increase Because of Obesity

10. CONCLUSIONS

10.1 Multiple Myeloma Treatment is a Thriving Market That Will Continue to Expand from 2012 to 2022
10.2 The R&D Pipeline for Multiple Myeloma Treatment is Large and Diverse
10.3 Biological Drugs Will Transform This Market
10.4 The Industry has Commercial Challenges to Overcome
10.5 Concluding Remarks

List Of Tables

LIST OF TABLES

Table 3.1 Global Multiple Myeloma Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 3.2 Multiple Myeloma Pipeline Candidates: Large Companies, 2012
Table 3.3 Celgene Corporation's Key Multiple Myeloma Products, 2012
Table 3.4 Johnson & Johnson's Key Multiple Myeloma Products, 2012
Table 3.5 Novartis's Key Multiple Myeloma Products, 2012
Table 3.6 Bristol-Myers Squibb's Key Multiple Myeloma Products, 2012
Table 3.7 Onyx Pharmaceutical's Key Multiple Myeloma Products, 2012
Table 3.8 Cephalon's Key Multiple Myeloma Products, 2012
Table 3.9 Aeterna Zentaris's Key Multiple Myeloma Products, 2012
Table 3.10 Merck & Co.'s Key Multiple Myeloma Products, 2012
Table 3.11 Takeda's Key Multiple Myeloma Products, 2012
Table 3.12 Pfizer's Key Multiple Myeloma Products, 2012
Table 3.13 Leading National Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 3.14 US Market: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 3.15 Japanese Market: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 3.16 EU5 National Markets: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 3.17 BRIC Markets: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 4.1 Leading Products in the Multiple Myeloma Market, Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 4.2 Revlimid Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 4.3 Thalomid Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 4.4 Actimid Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 4.5 Velcade Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 4.6 Kyprolis Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 5.1 Products in Late-Stage Development, 2012
Table 5.2 Selected Late-Stage Products in the Multiple Myeloma Market, Projected Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 5.3 Elotuzumab Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 5.4 MLN9708 Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 5.5 Perifosine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 5.6 Faridak Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 5.7 Aplidin Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 6.1 Phase III Small Molecule Compounds, 2012
Table 6.2 Phase II Small Molecule Compounds, 2012
Table 6.3 Phase I/II Small Molecule Compounds, 2012
Table 6.4 Phase I Small Molecule Compounds, 2012
Table 6.5 Exploratory/Preclinical Small Molecule Compounds, 2012
Table 7.1 Phase III Biologic Compounds, 2012
Table 7.2 Phase II Biologic Compounds, 2012
Table 7.3 Phase I/II Biologic Compounds, 2012
Table 7.4 Phase I Biologic Compounds, 2012
Table 7.5 Preclinical Biologic Compounds, 2012
Table 8.1 Strengths and Weaknesses of the Market, 2012-2022
Table 8.2 Opportunities and Threats in the Market, 2012-2022

List Of Figures

LIST OF FIGURES

Figure 2.1 Distribution of Multiple Myeloma Incidence, 2008
Figure 3.1 Global Multiple Myeloma Market Forecast: Revenues ($m), 2011-2022
Figure 3.2 Global Multiple Myeloma Market: Established Leading Products vs Other Products, Revenues ($m), 2011-2022
Figure 3.3 Myeloma Market Breakdown by Mechanism of Action ($m), 2011
Figure 3.4 Myeloma Market Breakdown by Mechanism of Action ($m), 2022
Figure 3.5 Top Companies in the Multiple Myeloma Market: Revenues ($m), Market Share (%), 2011
Figure 3.6 Leading Regional Markets: Revenues ($m), 2011-2022
Figure 3.7 US: Multiple Myeloma Drug Market Penetration- Usage in Early Stages of Disease (%), 2011
Figure 3.8 US: Multiple Myeloma Drug Market Penetration- Usage in Later Stages of Disease (%), 2011
Figure 3.9 US Market: Revenues ($m), 2011-2022
Figure 3.10 Japanese Market: Revenues ($m), 2011-2022
Figure 3.11 EU5 Markets: Revenues ($m), 2011-2022
Figure 3.12 EU Multiple Myeloma Market: Penetration of Top 3 Drugs (%), 2011
Figure 3.13 BRIC Markets: Revenues ($m), 2011-2022
Figure 4.1 Leading Products in the Multiple Myeloma Market, Market Share (%), 2011
Figure 4.2 Leading Products in the Multiple Myeloma Market, Revenues ($m), 2011-2022
Figure 4.3 Drivers and Restraints for Revlimid, 2012
Figure 4.4 Revlimid Market Forecast: Revenues ($m), 2011-2022
Figure 4.5 Thalomid Drivers and Restraints, 2012
Figure 4.6 Thalomid Market Forecast: Revenues ($m), 2011-2022
Figure 4.7 Actimid Drivers and Restraints, 2012
Figure 4.8 Actimid Market Forecast: Revenues ($m), 2011-2022
Figure 4.9 Velcade Drivers and Restraints, 2012
Figure 4.10 Velcade Market Forecast: Revenues ($m), 2011-2022
Figure 4.11 Kyprolis Drivers and Restraints, 2012
Figure 4.12 Kyprolis Market Forecast: Revenues ($m), 2011-2022
Figure 5.1 Selected Late-Stage Products for Multiple Myeloma: Projected Revenues ($m), 2011-2022
Figure 5.2 Drivers and Restraints for Elotuzumab and Other New Myeloma MAbs, 2012
Figure 5.3 Elotuzumab Market Forecast: Revenues ($m), 2011-2022
Figure 5.4 Drivers and Restraints for MLN9708 and Other New Oral Proteasome Inhibitors, 2012
Figure 5.5 MLN9708 Market Forecast: Revenues ($m), 2011-2022
Figure 5.6 Drivers and Restraints for Perifosine and Other New Protein Kinase Inhibitors, 2012
Figure 5.7 Perifosine Market Forecast: Revenues ($m), 2011-2022
Figure 5.8 Drivers and Restraints for Faridak and Other HDAC Inhibitors, 2012
Figure 5.9 Faridak Market Forecast: Revenues ($m), 2011-2022
Figure 5.10 Drivers and Restraints for Aplidin and Other Apoptosis Inducers, 2012
Figure 5.11 Aplidin Market Forecast: Revenues ($m), 2011-2022
Figure 6.1 Distribution of Small Molecules Drugs in Development (%), 2012
Figure 7.1 Distribution of Biologic Drugs in Development (%), 2012

COMPANIES LISTED

AB Science
Abbott
Abiogen
Acceleron
AdaptImmune
Aeterna Zentaris
Allos Therapeutics
Alza
Amgen
Ariad Pharmaceuticals
Arkansas Cancer Research Center
Arno Therapeutics
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Bayer
Ben Venue Laboratories
Biogen Idec
Biotest Pharmaceuticals
Boehringer Ingelheim
Bristol-Myers Squibb
Broad Institute
Calistoga Pharmaceuticals
Callisto Pharmaceuticals
Cancer Research UK
Celgene
Cell Genesys
Cephalon
Chiron
Chugai Pharmaceuticals
Columbia University
CombinatoRx
Compugen
Constellation Pharmaceuticals
Curis
CyDex
Cytokinetics
Cytopia
CytRx Corporation
Eli Lilly
EntreMed
Epizyme
European Medicines Agency (EMEA/EMA)
Facet Biotech
Food and Drug Administration (US FDA)
Genentech
Genmab
Genzyme
Geron
GlaxoSmithKline
Handok
Human Genome Sciences
Immune System Therapeutics
ImmunoGen
Immunomedics
Incyte Corporation
Infinity Pharmaceuticals
Intellikine
Italfarmaco
Jakafi
Janssen
Johnson & Johnson
Karyopharm Therapeutics
Kayaku Zentaris
Keryx Biopharmaceuticals
Kirin Pharma
Kosan Biosciences
Kyowa Hakko Kirin
Lipomed
MacroGenics
Mayo Clinic
MD Anderson Cancer Center
Merck & Co.
MethylGene
Micromet
Millennium Pharmaceuticals
MorphoSys
Multiple Myeloma Research Consortium (MMRC)
Multiple Myeloma Research Foundation
Natco Pharma
National Cancer Institute
National Institute for Health and Clinical Excellence (NICE)
Nereus Pharmaceuticals
Nippon Shinyaku
Novartis
Novo Nordisk
Oncolytics
Oncovir
Ono
Onyx Pharmaceuticals
PDL BioPharma
Pfizer
Pharmacia
Pharmacyclics
PharmaMar
Pierre Fabre
Prochon Biotech
Prometheus Labs
Protein Design
Regeneron
Roche
Rockefeller University
Salmedix
Schering-Plough
Scios
Seattle Genetics
Senesco Technologies
Sidney Kimmel CCC
Sloan Kettering
Sugen
Sun Pharma
Sydney Kimmel CCC
Synta Pharmaceuticals
Takeda
Targa Therapeutics
Teva Pharmaceutical Industries
Threshold Pharmaceuticals
Translational Genomics Research Institute
UAMS
University of Arkansas
University of Illinois
Vertex
Weill Cornell Medical College
World Health Organization (WHO)
Xencor
Zeltia
Zenyaku Kogyo